Back to search

Peptide record

TPDB09972

R2PLx-22 Antibacterial Anticancer Antifungal Toxicity standard
22 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09972
R2PLx-22
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 dbACP Antifungipept CAFPdb
standard
No
A 22-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
GIMDTVKNAAKNLAGQLLDKLK
Physicochemical Analysis
C102H181N29O31S1
RCEHFPSWY
LK
2341.79
10.16
4
2
10
+2
4.78
-0.155
115.45
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
4
Residue Composition
number
3
A
0
R
2
N
2
D
0
C
0
E
1
Q
2
G
0
H
1
I
4
L
4
K
1
M
0
F
0
P
0
S
1
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 3 R: 0 N: 2 D: 2 C: 0 E: 0 Q: 1 G: 2 H: 0 I: 1 L: 4 K: 4 M: 1 F: 0 P: 0 S: 0 T: 1 W: 0 Y: 0 V: 1
Chemical Descriptors
22
C102H181N29O31S1
2341.79
10.16
+2
4.78
-0.155
Free
L
Linear
Free
Antimicrobial
Synthetic Analogue of Ranatuerin-2PLx Synthetic
Evidence Records 10 records
Evidence 1 Activity

Activity

IC50
IC50 = 843.40 µM
Anticancer
843.40 µM

Target

Lung Cancer
H-157
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 872.70 µM
Anticancer
872.70 µM

Target

Skin Cancer
MDA-MB-435S
Skin

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 3 Activity

Activity

IC50
IC50 = 283.90 µM
Anticancer
283.90 µM

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 4 Activity

Activity

IC50
IC50 = 104.10 µM
Anticancer
104.10 µM

Target

Brain Tumor
U-251-MG
Brain

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 5 Activity

Activity

IC50
IC50 = 109.30 µM
Anticancer
109.30 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 6 Activity

Activity

IC50
Toxicity
588.20 µM
Cytotoxic
IC50 | 588.20 | µM | target cell: Human microvascular endothelial cells HMEC-1

Target

Human microvascular endothelial cells HMEC-1

Source & Reference

NA
DBAASP
A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells | Biosci Rep | 2018
Evidence 7 Activity

Activity

13% Hemolysis
Toxicity
512 µM
Hemolytic Cytotoxic
13% Hemolysis | 512 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells | Biosci Rep | 2018
Evidence 8 Activity

Activity

<5% Hemolysis
Toxicity
256 µM
Hemolytic Cytotoxic
<5% Hemolysis | 256 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells | Biosci Rep | 2018
Evidence 9 Activity

Activity

% Hemolysis
Toxicity
3 %
Hemolytic
Hemolytic_activity: [Ref.30279210] 3% hemolysis at 1 µM , 4% hemolysis at 2 µM , 1% hemolysis at 4 µM , 0% hemolysis at 8 µM , 2% hemolysis at 16 µM , 0% hemolysis at 32 µM , 0% hemolysis at 128 µM , 3% hemolysis at 256 µM , 13% hemolysis at 512 µM against human red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
Biosci Rep. 2018 Nov 9 38(6). pii: BSR20180710. doi: 10.1042/BSR20180710.
Evidence 10 Activity

Activity

IC50
Toxicity
588.20 µM
Hemolytic Cytotoxic
Hemolytic_activity: Horse erythrocytes: Low haemolytic activity | Cytotoxicity: HMEC-1: IC50=588.20 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Biosci Rep. 2018 Nov 9 38(6):BSR20180710.